Patient | Age (year), gender | Germline status | Tumor profile | Number of prior lines of chemotherapy | Metastatic sites at ICI initiation | ICI | First and last infusion of ICI | Reason of ICI discontinuation | Overall best response | Best response of adrenal gland metastasis | PD of adrenal gland metastasis (date) | Treatment of adrenal gland progression (date) | PD on other metastatic sites (date) | The last follow-up visit (status) |
#1 | 61, F | Sporadic case | MSI, MLH1-neg, BRAFmt | 1 | Liver, lymph nodes | Anti-PD1 +anti-CTLA4 | 06/2015 to 07/2015 | Necrotizing myositis | PR | NA (not present at baseline) | 03/2016 | Adrenalectomy (08/2016) | No | 07/2020 (free of progression) |
#2 | 44, M | Lynch syndrome | MSI, MSH2-neg, RAS/RAF-wt | 2 | Adrenal gland liver, lymph nodes, | Anti-PD1 +anti-CTLA4 | 05/2016 to 03/2018 | PD (adrenal gland) | PR | SD | 03/2018 | SBRT (06/2018) | No | 06/2020 (free of progression) |
#3 | 45, M | Lynch syndrome | MSI, MSH2-neg, KRAS-mt | 3 | Adrenal gland liver, lymph nodes | Anti-PD1 +anti-CTLA4 | 09/2016 to 11/2019 | PD (adrenal gland) | PR | SD | 12/2019 | SBRT (03/2020) | No | 06/2020 (free of progression) |
#4 | 52, M | Lynch syndrome | MSI MSH6-neg MSH6-neg | 0 | Peritoneum | Anti-PD1 | 07/2017 To 02/2019 | Grade 3 colitis | CR | NA (not present at baseline) | 12/2019 | Adrenalectomy (03/2020) | No | 06/2020 (free of progression) |
#5 | 77, F | Unknown | MLH1-neg PMS2-neg βcatenine-mt | 3 | Lung, lymph nodes | Anti-PD1 +anti-CTLA4 | 01/2019 To 01/2020 | PD (adrenal gland) | SD | NA (not present at baseline) | 12/2019 | Adrenalectomy (03/2020) | No | 06/2020 (free of progression) |
CR, complete response; ICI, immune checkpoint inhibitor; MSI, microsatellite instability; mt, mutated; neg, negative; PD, progressive disease; PR, partial response; SBRT, stereotactic body radiation therapy; SD, stable disease; wt, wild type.